趋势:Pet sitting marketplace Rover grabs a bone, valued at $1.3 billion in latest SPAC deal
Dr. Hans-Peter Kiem of the Fred Hutchinson Cancer Research Center. (Fred Hutch Photo)

新的旋转:Boston-based biotech startupEnsoma.星期四推出,并宣布了7000万美元的一系列资金。本公司建于西雅图研究人员两十年多年来开发的技术Dr. Hans-Peter KiemFred Hutchinson癌症研究中心和andré利伯斯博士作者:王莹,华盛顿医学院学报JOURNAL。

该公司将在波士顿,因为城市“是生物技术的震中和雄肿可以迅速吸引人才,不仅用于研究,而且作为公司在制造和临床发展中的尺度,”说Paula Soteropoulos.,公司执行主席。该公司的主要投资者和最高领导层也在波士顿。

生物技术战略:The company’s Engenious vectors are designed to deliver gene therapies to patients without requiring stem cell donation or pre-treatments such as chemotherapy. The therapy can treat a variety of ailments including rare diseases, cancer, autoimmune disease, and infectious diseases. Another benefit is the treatment can be given in a single injection in settings that include outpatient clinics.

andré利伯斯博士作者:王莹,华盛顿医学院学报JOURNAL。(UW Photo)

更深入:载体可以携带长长的延伸靶向各种细胞类型的遗传物质,包括在骨髓中发现的造血干细胞,或从干细胞产生的细胞,B细胞和骨髓细胞如T细胞。作为工程腺病毒载体的载体提供遗传物质,可以在遗传密码中编辑误差,插入基因组信息或修饰基因表达。

In 2019, Kiem gave aTedxseattle.talk on the science involved.

创始人血统:Kiem, who is director of the Stem Cell and Gene Therapy Program at the Fred Hutch, and Lieber, a professor with the UW’s Division of Medical Genetics, will be scientific co-founders of Ensoma. Kiem will be Ensoma’s chief scientific and clinical advisor. Both earned advanced academic degrees in Germany.

Soteropoulos is a biotech veteran who previously founded Akcea Therapeutics and was an exec at Moderna and Sanofi Genzyme. She is a strategic advisor for 5AM Ventures, a venture firm with offices in Boston and San Francisco and Ensoma’s lead investor.

Kush Parmar博士,Ensoma的首席执行官,是凌晨5点售价的管理伙伴。

“Because our in vivo therapies do not require prior conditioning or stem cell donors, we hope to deliver them as ‘off-the-shelf’ treatments to address diseases — both rare and common — dramatically simplifying the logistics of scaling production and reducing patient and healthcare-system burden,” Soteropoulos said in a statement. “Every person, no matter where they are in the world, should have access to the innovative technologies that are changing the way we treat disease.”

Spinout success:OtherFred Hutch spinoutsinclude Juno Therapeutics and Adaptive Biotechnologies, while University of Washington research led to the launch of Icosavax, Neoleukin Therapeutics, Universal Cells, Cyrus Biotechnology and others.

Investor interest:该融资由联合创始人和Seed Investor 5am Ventures参与来自F-Prime Capital,Takeda Ventures,Viking Global Investors,Cormorant Capital,Rit Capital Partners,Alexandria Venture Intruments and Symbiosis II。资金包括潜在额外的1亿美元的“前端和临床前研究支付”,以与Takeda合作。

喜欢你在读什么?订阅Geekwire的免费新闻通讯以捕捉每个标题

Geekwork上的工作列表

找到更多的工作极客. Employers,岗位.